Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Assets: 2022-2025

Historic Assets for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $240.3 million.

  • Phathom Pharmaceuticals' Assets fell 37.92% to $240.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.3 million, marking a year-over-year decrease of 37.92%. This contributed to the annual value of $378.3 million for FY2024, which is 8.58% down from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Assets stood at $240.3 million, which was down 3.97% from $250.2 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Assets high stood at $413.8 million for Q4 2023, and its period low was $144.0 million during Q1 2023.
  • Moreover, its 3-year median value for Assets was $294.2 million (2025), whereas its average is $298.7 million.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Assets surged by 151.10% in 2023, and later tumbled by 37.92% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' Assets (Quarterly) stood at $164.8 million in 2022, then surged by 151.10% to $413.8 million in 2023, then decreased by 8.58% to $378.3 million in 2024, then tumbled by 37.92% to $240.3 million in 2025.
  • Its Assets stands at $240.3 million for Q3 2025, versus $250.2 million for Q2 2025 and $294.2 million for Q1 2025.